Scoping Before Coding: How a Technology Consultant De-Risks a Custom Hub Platform for US Specialty Pharmacy and Hub Service Leaders

Measure Where Your Patients Are Waiting

Before any platform conversation, and before hub platform scoping can produce a defensible number, take a hundred recent cases and measure time to therapy broken into stages.

Days at benefits investigation. Days at prior authorization. Days at appeal where there was one. Days at assistance enrollment. Days between approval and shipment. Days between shipment and first dose.

Most organizations measure the total and are surprised by the distribution, which typically shows that one or two stages carry most of the time and that the time within them is overwhelmingly queue rather than work.

That finding determines what a platform should address and whether it would help at all, since a queue problem is sometimes a staffing or routing problem a system will not solve.

It also gives a leadership team a number expressed in days a patient waited, which is the right unit for this business.

The exercise takes a few days, uses records the organization already has, and is where hub platform scoping should begin. Scoping is the decision layer of the full custom software development guide to custom specialty pharmacy hub platform development, whose working surfaces are web application development for the staff who run the operation.

The Second Exercise: Test the Bifurcation

Ask somebody to attempt, in your current system, to enroll a Medicare patient in a manufacturer copay program.

Not to actually do it. To find out whether the system would stop them, warn them, or allow it.

Then ask what happens when a commercially insured patient on therapy becomes Medicare eligible. Does anything detect the change, and does anything reassess the assistance they are receiving.

Most organizations discover the control is procedural rather than structural: a trained coordinator who knows the rule, a form that asks the question, a review somebody performs.

Trained people are a genuine control and they are not a complete one, particularly at volume, with turnover, under time pressure, with a patient on the phone who cannot afford their medication.

That finding is the clearest argument for whatever follows, and it is also actionable immediately regardless of any platform decision.

A third quick check completes it: whether anybody can say what was reported to each manufacturer last quarter and under which agreement version.

What Scoping Should Settle

The Regulatory Architecture

The payer bifurcation, the reporting boundary and the dispensing blocks, settled with healthcare regulatory counsel and the compliance officer before any design work. Two of these cannot be retrofitted, which is why they are first rather than last.

The Manufacturer Agreement Inventory

Every program the organization operates, what each agreement permits in reporting, what each requires operationally, and what integration each involves. Sizes the permanent maintenance cost and is the item that most often decides build against buy.

The Time to Therapy Analysis

The staged measurement extended, with queue time separated from work time and the dominant stages identified. Determines whether software addresses the actual constraint and gives the business case in days a patient waited.

The Accreditation Position

Which bodies, which standards version, which performance metrics are required and which are currently collected systematically. Organizations pursuing first accreditation routinely underestimate the measurement gap.

The Verification Reality

What proportion of benefit investigations complete electronically and what proportion require a call, by payer and benefit type. Determines integration value and the size of the specialist workspace, which is where the hours actually go.

The positions scoping must settle are set out in URAC and ACHC Specialty Accreditation, HIPAA, Manufacturer Data Reporting Agreements, Anti-Kickback Limits on Patient Assistance and REMS Program Requirements.

What the Leadership Team Receives

A regulatory architecture specification covering the bifurcation, the reporting boundary and the dispensing blocks, agreed with counsel and the compliance officer, which is the document the build is held against.

A manufacturer agreement inventory with reporting requirements and integration effort per program.

A time to therapy analysis by stage with queue time separated, expressed in patient days.

An accreditation readiness assessment with the measurement gap identified. A verification reality report sizing the electronic and manual split.

A current-state control assessment from the bifurcation test, with anything needing immediate attention flagged, since that finding is live now.

A platform evaluation against the specialized vendors, tested specifically on regulatory architecture rather than on feature lists.

A defined MVP with the compliance elements identified as non-deferrable and the breadth reductions that are legitimately deferrable.

And a costed comparison of at least three paths, adopt a specialized platform, adopt and build the integration layer, and build fully, with manufacturer maintenance shown as a permanent allocation in the last. The budget scoping protects is detailed in Custom Specialty Pharmacy Hub Platform Pricing in 2026.

Reading the Recommendation

Adopt a specialized platform when its regulatory architecture is sound and it supports your manufacturer programs, which for most specialty pharmacies is the answer and where the maintained compliance architecture is the decisive argument.

Adopt and build the integration layer when the gap is connection to your own clinical, dispensing and financial systems rather than hub functionality, which for health system pharmacies is frequently the real position.

Build fully when program mix is genuinely poorly served, when the operating model is distinctive, or when a large hub operator’s scale justifies carrying the architecture.

Fix the process when the time to therapy analysis shows the constraint is staffing or routing within a stage, which happens and which no platform resolves.

One consideration applies whichever path is chosen. If the bifurcation test showed a procedural rather than structural control, that is a live exposure and deserves attention this quarter independent of any software decision.

And a consultant who leads with the compliance architecture rather than the feature list has understood the category.

What a Consultant Should Know About This Business

Four questions establish whether a consultant has worked in specialty pharmacy.

Ask what happens when a Medicare patient needs financial help. A good answer immediately distinguishes manufacturer copay assistance from foundation referral and explains why. Anyone treating assistance as one capability has not worked here.

Ask whether that should be a rule or a structure. The right answer is structural, with no override, because a procedural control fails at volume. Anyone describing it as a configuration setting has proposed the wrong architecture.

Ask how adherence outreach should be scheduled. A good answer says clinical protocols. Anyone proposing discontinuation-risk scoring to target outreach has described a program that is not patient support, and the conversation should end there.

And ask about manufacturer reporting. A consultant who talks about bounded per-program outputs and agreement versions understands the constraint; one who describes a reporting module with configurable exports does not.

Red Flags in the Conversation

Scoping offered free and contingent on winning the build. A fixed price before the manufacturer agreement inventory exists. Compliance described as a later phase. No counsel or compliance officer involvement proposed. No platform comparison. Accreditation measurement absent from scope.

And the ones that should end the conversation: assistance eligibility presented as a configurable rule with override, discontinuation-risk scoring offered to target outreach, persistence presented as a success metric, REMS conditions implemented as dismissible warnings, manufacturer reporting described as a flexible export, and any suggestion that program data could inform commercial targeting.

The strongest positive signal is a partner who asks to sit with a benefits specialist for a day and listen to the calls.

Conclusion

Measure time to therapy by stage and test whether your bifurcation control is structural or procedural, since both use what you already have and both frequently change the conversation.

Settle the regulatory architecture with counsel before any design, because two of its three elements cannot be retrofitted.

And weigh the specialized platforms on compliance architecture rather than features, since that is the part a single organization otherwise maintains alone. Apply that hub platform scoping standard to every partner, including the software companies in the United States who would like to build it.

If you are weighing a custom hub platform, measuring a hundred cases for time to therapy by stage is the few days to spend before any vendor conversation.

FAQ